Editor's note: From April 24 to 27, 2024, the Advanced Prostate Cancer Consensus Conference was held in Lugano, Switzerland. The conference brought together more than 100 top experts from around the world to discuss and develop a consensus on the diagnosis and treatment of advanced prostate cancer.
在这次大会上，作为中国大陆唯一的代表，叶定伟教授受邀进行了题为《How to deal with the projected rise of prostate cancer cases in the Chinese healthcare system》的发言。
It is understood that APCCC is a high-end meeting of global experts in the field of prostate cancer, which is held every two years to release the St. Gallen consensus on the diagnosis and treatment of advanced prostate cancer. As a representative of Chinese mainland, Professor Ye Dingwei was invited to participate in three consecutive sessions and participated in the formulation of consensus.
At the conference, Prof. Ip shared a number of measures taken by China's healthcare system to address the growing incidence of prostate cancer and the challenges of diagnosis and treatment. He introduced China's progress in prostate cancer screening, localization of medical equipment, research and development of new drugs, improvement of medical insurance coverage and patient education. Professor Ye Dingwei's report has attracted wide attention and discussion in the field of international prostate cancer.
The Department of Urology, Fudan University Cancer Hospital, led by Professor Ye Dingwei, has become the largest, most influential and most extensive prostate cancer diagnosis and treatment and research center in China. Professor Ye Dingwei has personally completed more than 2,000 robotic radical prostatectomy, demonstrating his rich experience in diagnosis and treatment. His team focuses on the development of new surgical technologies, with an annual robotic operation volume of more than 1,000 units, and has made remarkable achievements in the research of new robotic technologies, such as leading the clinical development of the first "Haishanyi" surgical robot system in China.
In addition, Prof. Yip's team also attaches great importance to integrated treatment and clinical research, including a number of ongoing studies of new ADC drugs, novel nuclides and novel immunotherapies. According to the public data of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration, Professor Ye Dingwei has led nearly 100 international and domestic clinical studies and achieved a number of research results. The team has also published an article in the top journal "Nature Reviews Urology" to review the disease characteristics of prostate cancer in Asia and the characteristics of prostate cancer with high-grade liver metastases. With the efforts of the team, the 5-year survival rate of prostate cancer patients diagnosed and treated by Fudan University Cancer Hospital has reached 82.6%, which is leading in China and comparable to the level of Asia-Pacific and European and American countries.
Copyright Notice
The copyright of this article belongs to the Department of Urology, Fudan University Cancer Hospital.